Instil Bio, Inc. Increase (Decrease) in Accrued Investment Income Receivable
Instil Bio, Inc. (TIL) reported Increase (Decrease) in Accrued Investment Income Receivable of $607.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable · last filed 2026-08-13
- Instil Bio, Inc. increase (decrease) in accrued investment income receivable for the quarter ending 2026-06-30 was $303.00K, a 76.71% decline year-over-year.
- Instil Bio, Inc. increase (decrease) in accrued investment income receivable for the quarter ending 2026-03-31 was $304.00K, a 78.16% decline year-over-year.
- Instil Bio, Inc. increase (decrease) in accrued investment income receivable for the quarter ending 2025-12-31 was $304.00K, a 89.04% decline year-over-year.
- Instil Bio, Inc. increase (decrease) in accrued investment income receivable for the quarter ending 2025-09-30 was $400.00K.
- Instil Bio, Inc. increase (decrease) in accrued investment income receivable for fiscal 2025 was $3.40M, a 20.39% decline from fiscal 2024.
- Instil Bio, Inc. increase (decrease) in accrued investment income receivable for fiscal 2024 was $4.27M.
| Period end | Increase (Decrease) in Accrued Investment Income Receivable 3 month | Increase (Decrease) in Accrued Investment Income Receivable 6 month | Increase (Decrease) in Accrued Investment Income Receivable 9 month | Increase (Decrease) in Accrued Investment Income Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $303.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $607.00K 10-Q · filed 2026-08-13 | $911.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $304.00K 10-Q · filed 2026-05-15 | $608.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.01M derived: sum of 3 quarters · filed 2026-05-15 | $2.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $704.00K derived: sum of 2 quarters · filed 2026-03-27 | $2.00M derived: sum of 3 quarters · filed 2026-08-13 | $3.40M 10-K · filed 2026-03-27 |
| 2025-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.70M derived: sum of 2 quarters · filed 2026-08-13 | $3.09M 10-Q · filed 2025-11-13 | $5.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.69M 10-Q · filed 2026-08-13 | $5.47M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | $1.39M 10-Q · filed 2026-05-15 | $4.17M derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $4.27M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | $1.49M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |